Study to Assess the Safety and Efficacy of Evexomostat (SDX-7320) in Combination With A PI3K or Akt Inhibitor Plus Fulvestrant in Patients With HR+, HER2-, Metastatic Breast Cancer With PI3K Pathway Alteration(s)

This study is testing a new drug combination for people with a specific type of advanced breast cancer that has spread to other parts of the body. The goal is to see if adding a new medicine called 'evexomostat' to standard treatments can fight the cancer more effectively while also reducing common side effects like high blood sugar.

This trial is for men and post-menopausal women with HR+, HER2- breast cancer that has specific genetic changes in the PI3K pathway. You must have advanced or metastatic cancer, and your doctor will check if your specific tumor profile matches what this study is looking for.

Participants will receive a 'triplet therapy,' which means taking a combination of three different drugs to treat the cancer. During the study, your medical team will closely monitor your blood sugar levels, tumor response, and overall quality of life to ensure the treatment is safe and effective for you.

The study is currently recruiting patients at locations in Loma Linda, Newport, and San Diego, California. You should talk to your oncology team to see if one of these centers is a good fit for your care.